Sugi Predict

Sugi Predict / Compounds / SCHEMBL7327360

SCHEMBL7327360

SCHEMBL7327360

Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GABRA1 P14867 6/20 0.79
▸ GABRA5 P31644 6/20 0.79
▸ GABRA2 P47869 6/20 0.79
▸ GABRA3 P34903 4/20 0.79
▸ OPRK1 P41145 3/20 0.79
▸ PDE4D Q08499 2/20 0.79
▸ GABRG2 P18507 1/20 0.79
▸ HTR2A P28223 1/20 0.79
▸ GABRB3 P28472 1/20 0.79
▸ ADRA1A P35348 1/20 0.79
▸ PTAFR P25105 7/20 0.76
▸ GABRB2 P47870 5/20 0.73
▸ HPGD P15428 2/20 0.73
▸ BRD4 O60885 2/20 0.73
▸ LMNA P02545 2/20 0.73
▸ CNR1 P21554 1/20 0.73
▸ SMN1; SMN2 Q16637 2/20 0.73
▸ CYP3A4 P08684 2/20 0.68
▸ SLC22A1 O15245 1/20 0.68
▸ ABCB11 O95342 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29369120 1.00 GABRA1 (0.79) GABRA1GABRA5GABRA2GABRA3OPRK1
SCHEMBL7317622 0.89 GABRA1 (0.70) GABRA1GABRA5GABRA2GABRA3OPRK1
SCHEMBL14282558 0.88 PTAFR (0.79) GABRA1GABRA5GABRA2GABRA3OPRK1
SCHEMBL11620188 0.88 PTAFR (0.79) GABRA1GABRA5GABRA2GABRA3OPRK1
Triazolam SCHEMBL29382425 0.88 GABRA1 (1.00) GABRA1GABRA5GABRA2GABRA3OPRK1
Triazolam SCHEMBL29228 0.88 GABRA1 (1.00) GABRA1GABRA5GABRA2GABRA3OPRK1
Triazolam SCHEMBL29349744 0.88 GABRA1 (1.00) GABRA1GABRA5GABRA2GABRA3OPRK1
Triazolam SCHEMBL29368430 0.88 GABRA1 (1.00) GABRA1GABRA5GABRA2GABRA3OPRK1
Triazolam SCHEMBL5142333 0.88 GABRA1 (1.00) GABRA1GABRA5GABRA2GABRA3OPRK1
Midazolam SCHEMBL20658917 0.88 OPRK1 (0.79) GABRA1GABRA5GABRA2GABRA3OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0345931-B1 CERTAIN PAF ANTAGONIST/ANTIHISTAMINE COMBINATIONS AND METHODS SCHERING CORPORATION (US) 1993-01-20 — — EP claimed
EP-0402422-A1 CERTAIN PAF ANTAGONIST ANTIHISTAMINE COMBINATIONS AND METHODS SCHERING CORPORATION (US) 1990-12-19 — — EP claimed
WO-1989010143-A1 CERTAIN PAF ANTAGONIST ANTIHISTAMINE COMBINATIONS AND METHODS SCHERING CORPORATION (US) 1989-11-02 — — WO claimed
US-3987052-A SEDATIVES, TRANQUILIZERS, MUSCLE RELAXANTS THE UPJOHN COMPANY (US) 1976-10-19 — — US claimed
US-20230142171-A1 NEW BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM HOFFMANN-LA ROCHE INC. (US) 2023-05-11 — — US disclosed
US-20230142171-A1 NEW BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM HOFFMANN-LA ROCHE INC. (US) 2023-05-11 — — US disclosed
CN-115232133-A D3-flualprazolam and preparation method thereof 公安部物证鉴定中心 2022-10-25 — — CN disclosed
WO-2015081280-A1 BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION COFERON, INC. (US) 2015-06-04 — — WO disclosed
WO-2015081284-A1 BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME COFERON, INC. (US) 2015-06-04 — — WO disclosed
US-20140243322-A1 BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME COFERON, INC. (US) 2014-08-28 — — US disclosed
US-20140243321-A1 BIOORTHOGONAL MONOMERS CAPABLE OF DIMERIZING AND TARGETING BROMODOMAINS, AND METHODS OF USING SAME COFERON, INC. (US) 2014-08-28 — — US disclosed
US-20140243321-A1 BIOORTHOGONAL MONOMERS CAPABLE OF DIMERIZING AND TARGETING BROMODOMAINS, AND METHODS OF USING SAME COFERON, INC. (US) 2014-08-28 — — US disclosed
US-20090130216-A1 MULTIMODAL PARTICULATE FORMULATIONS HALE BIOPHARMA VENTURES 2009-05-21 — — US disclosed
US-5334592-A Administering for allergic reactions; thienotriazolodiazepine compounds SCHERING CORPORATION (US) 1994-08-02 — — US disclosed
EP-0345931-B1 CERTAIN PAF ANTAGONIST/ANTIHISTAMINE COMBINATIONS AND METHODS SCHERING CORPORATION (US) 1993-01-20 — — EP disclosed
EP-0402422-A1 CERTAIN PAF ANTAGONIST ANTIHISTAMINE COMBINATIONS AND METHODS SCHERING CORPORATION (US) 1990-12-19 — — EP disclosed
WO-1989010143-A1 CERTAIN PAF ANTAGONIST ANTIHISTAMINE COMBINATIONS AND METHODS SCHERING CORPORATION (US) 1989-11-02 — — WO disclosed
US-4000289-A 6-PHENYL-4H-S-TRIAZOLO(4,3-A)(1,4)BENZODIAZEPINES THE UPJOHN COMPANY (US) 1976-12-28 — — US disclosed
US-3987052-A SEDATIVES, TRANQUILIZERS, MUSCLE RELAXANTS THE UPJOHN COMPANY (US) 1976-10-19 — — US disclosed
US-3984545-A 3,4-DIHYDROXY-PHENYL-1-ANALINE WITH BENZODIAZEPINES THE UPJOHN COMPANY (US) 1976-10-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243322-A1 BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME BRDT, BRD2, BRD4 GABRA1 966/4885GABRA5 1367/4885GABRA2 768/4885
US-20090130216-A1 MULTIMODAL PARTICULATE FORMULATIONS MTNR1B, MTNR1A, SERPINA6 GABRA1 2797/4885GABRA5 2351/4885GABRA2 2494/4885
US-20140243321-A1 BIOORTHOGONAL MONOMERS CAPABLE OF DIMERIZING AND TARGETING BROMODOMAINS, AND METHODS OF USING SAME BRDT, BRD4, BRD1 GABRA1 1095/4885GABRA5 2087/4885GABRA2 1159/4885
US-20230142171-A1 NEW BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM GABRA1, GABRB1, GABRA5 GABRA1 1/4885GABRA5 3/4885GABRA2 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.